Overview

• Radiopharmaceutical firm's Q4 revenue rose 4%, beating analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

• Company repurchased $100 mln of shares in Q4

Outlook

• Company provides full-year 2026 revenue guidance of $1.4 bln to $1.45 bln

• Lantheus expects 2026 adjusted EPS between $5.00 and $5.25

• Company aligns strategic focus on PET radiodiagnostics for sustainable growth

Result Drivers

• STRATEGIC FOCUS - Co is sharpening focus on PET radiodiagnostics and pursuing alternatives for radiotherapeutic assets for long-term growth

• PORTFOLIO EXPANSION - Co expanded its commercial portfolio with Neuraceq and acquisitions of Life Molecular Imaging and Evergreen Theragnostics

• PRODUCT LAUNCH READINESS - Co is ensuring launch readiness for new products with up to four FDA approvals expected in 2026

Company press release: ID:nGNXbR32pg

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Lantheus Holdings Inc is $80.00, about 5.7% above its February 25 closing price of $75.72

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 10 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)